The Financial Times has described Frank Aquila as “one of the most influential and high-profile M&A and corporate lawyers in the U.S.” who has “played a role in many of the largest and most complex deals.” In December 2019, Frank was one of the dealmakers profiled in an article in The Financial Times titled “Deal lawyers are masters of seeing the next move.” The Wall Street Journal profiled him as one of the six top dealmakers of the year in 2019 and one of the seven top dealmakers in 2018. In October 2021, he was profiled by Insider as one of the world’s top “M&A lawyers leading the way today, closing billion-dollar blockbuster deals.”
During the course of his career, Frank has advised on deals totaling more than $1 trillion in value, including advising on more than $150 billion in 2015 and more than $100 billion in 2019. He has been called upon by global leaders such as Amgen, Andeavor, Anheuser-Busch InBev, Baxter International, Biohaven Pharmaceuticals, Canadian Pacific, Cheniere Energy, Cornerstone Building Brands, Diageo, Diebold Nixdorf, GameStop, Haleon, International Airline Group, Kering, Kraft, Navistar International, Novartis, Tiffany & Co. and United Rentals to advise them and their boards of directors on M&A, corporate governance, ESG, activism, proxy contests, unsolicited bids, ransomware attacks, short squeezes, crisis management and a range of matters affecting corporate policy and strategy.
Frank has been universally recognized as one of the world’s leading mergers and acquisitions lawyers. The strength of his practice has resulted in his being one of only a handful of lawyers who has been ranked by Chambers Global in Band 1 (their top tier), as a three-time American Lawyer “Dealmaker of the Year,” as a recipient of the Atlas Award as “Global M&A Lawyer of the Year” and as a three-time Law360 MVP. For his work in corporate governance, Frank has been named several times by the National Association of Corporate Directors (NACD) to their “Directorship 100” as one of the 100 most influential people in corporate governance and inside the boardroom. Best Lawyers in America named Frank as its 2017 Corporate Governance Law “Lawyer of the Year.” In 2014, Global M&A Network recognized him as one of the top 50 lawyers in the world. Since 2019, Frank has been featured as a BTI Client Service All-Star three times and was also designated a BTI Elite MVP All-Star in 2022. Also in 2022, Frank was recognized by Lawdragon as one of 20 lawyers selected as a “Lawdragon Legend of the 500.”
Frank is widely acknowledged as an innovator and thought leader in the profession. In 2018, he was recognized by The Financial Times as one of the Top 10 Legal Innovators in North America. In 2015, The FT also recognized his representation of Kraft in its merger with Heinz to form The Kraft Heinz Company as one of the most innovative in North America, and he led the Sullivan & Cromwell team that won The FT's top award in 2021 for Innovation in Transformational Deals for advising Tiffany & Co. in its $16 billion acquisition by LVMH. In 2009, Frank was selected by the American Bar Association as a “Legal Rebel” – one of the profession’s 50 leading innovators. In 2015, the National Law Journal named him as one of M&A’s “Trailblazers” for “excellence in dealmaking.” He is also a two-time winner of the Burton Award for Legal Achievement (2005, 2010). Frank led the Sullivan & Cromwell teams advising on The American Lawyer’s 2016 “Deal of the Year” – Kraft in its merger with Heinz and on The New York Times DealBook’s 2021 “Deal of the Year” – Canadian Pacific in its acquisition of Kansas City Southern.
As a leader in his field, Frank has advised numerous clients in many of the largest and most important global transactions that have been transformational across a range of business sectors. In pharmaceuticals he represented The Upjohn Company in its merger with Pharmacia to create Pharmacia & Upjohn, its subsequent acquisition of Monsanto to form Pharmacia and Biohaven Pharmaceuticals in its acquisition by Pfizer. In consumer healthcare Frank represented Haleon in its demerger from the GSK Group. In beverage alcohol Frank represented Grand Metropolitan in its combination with Guinness to form Diageo and Diageo in its acquisition of Seagram Wine & Spirits. In brewing he represented InBev in its successful bid for Anheuser-Busch and Anheuser-Busch InBev in its follow-on deals to acquire SABMiller, Grupo Modelo and Oriental Brewery, and in its Worldwide Olympic Partnership through 2028 with the International Olympic Committee, through which AB InBev’s Corona Cero will be the global beer sponsor of the Olympic Games. In biotech he represented Amgen in its acquisitions of Horizon Therapeutics, Abgenix, Onyx and Otezla® and Novartis in its acquisition of The Medicines Company. In aviation he represented British Airways in its combination with Iberia to form IAG International Airlines Group. In consumer packaged goods Frank represented Pillsbury in its combination with General Mills and Kraft in its merger with H.J. Heinz to form The Kraft Heinz Company. In equipment rental he represented United Rentals in its acquisitions of RSC, Neff Corporation and BlueLine Rental. In automated payment systems and ATMs Frank represented Diebold in its combination with Wincor Nixdorf to form Diebold Nixdorf. In food and beverage retailing Frank advised Subway in its pending acquisition by Roark Capital and Panera in its acquisition by JAB. In oil and gas Frank represented Andeavor in its acquisition by Marathon Petroleum. In luxury goods Frank represented Tiffany & Co. in its acquisition by LVMH Moët Hennessy Louis Vuitton. In medtech he represented Baxter International in its acquisition of Hillrom. In transportation he represented Canadian Pacific Railway in its acquisition of Kansas City Southern.
Frank is Sullivan & Cromwell’s Senior M&A Partner and has served the Firm in numerous senior management positions, including as a member of the Management Committee, as Global Head of the M&A Practice and as co-managing partner of the General Practice Group (the Firm’s global corporate practice).
Sending an e-mail through this web site does not
create an attorney-client relationship. You should not
send us any information through this web site that you
would want treated confidentially.
Sending an e-mail through this web site does not create an attorney-client relationship. You should not send us any information through this web site that you would want treated confidentially.